Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
NCT03415711 · VSL Pharmaceuticals · NA · terminated · last registry update 2020-01-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administrative reasons” | – | Registry record, VSL Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALOX5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-01-15Results posted on the registry: Gilead Sciences, Filgotinib + Placebo to match filgotinib (NCT02873936)
- 2020-12-31Results posted on the registry: University of Utah, Mesalamine + Placebo (NCT01412372)
- 2020-10-30Phase 3 first posted: University of Erlangen-Nürnberg Medical School, Prednisolone + Sulfasalazine (NCT04610476)
- 2020-08-14Results posted on the registry: Holy Stone Healthcare Co., Ltd, High dose + Low dose (NCT02493712)
- 2020-08-10Results posted on the registry: Sanofi, SARILUMAB + Azathioprine (NCT03449758)
- 2020-07-22Results posted on the registry: Hutchison Medipharma Limited, HMPL-004 low dose + Placebo (NCT00659802)
- 2020-06-17Phase 3 first posted: University Hospital, Ghent, week 24 + week 36 (NCT04435288)
- 2020-03-23Results posted on the registry: National Cancer Institute (NCI), Aspirin + Zileuton (NCT02348203)
- 2020-01-18Results posted on the registry: Shire, MMX Mesalamine/Mesalazine (Low Dose) + MMX Mesalamine/Mesalazine (High Dose) (NCT02093663)
- 2019-11-18Also stopped (terminated): University of Minnesota, Zileuton + Placebo (NCT00493974)
- 2019-11-01Results posted on the registry: Bausch Health Americas, Inc., Encapsulated Mesalamine Granules (eMG) (NCT00326209)
- 2019-10-15Results posted on the registry: Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-10-15Also stopped (terminated): Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-09-06Results posted on the registry: Bausch Health Americas, Inc., Budesonide MMX® + Placebo (NCT01532648)
- 2019-08-28Results posted on the registry: Connecticut Children's Medical Center, Mesalazine + IV Corticosteroid (NCT01536535)
- 2019-08-28Results posted on the registry: Forest Laboratories, MAX-002 + Placebo (NCT01016262)
- 2019-08-28Also stopped (terminated): Forest Laboratories, MAX-002 + Placebo (NCT01016262)
- 2019-05-14Results posted on the registry: University of Nebraska, Leflunomide + Methotrexate-Sulfasalazine-Hydroxychloroquine (NCT00579878)
- 2019-04-18Also stopped (terminated): Christoph Gasche, mesalamine 2400 MG (5-ASA) + mesalamine 1200 MG (NCT03070574)
- 2019-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, Meclofenamic acid + Pentosan polysulfate sodium (NCT02930005)
- 2019-01-29Also stopped (terminated): Annette Langseder, Asacol (NCT00349388)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision